• In late May and early June 2026, Agios Pharmaceuticals halted development of tebapivat in lower-risk myelodysplastic syndromes, gained European Commission approval for PYRUKYND (mitapivat) in thalassemia across all EU member states, and licensed exclusive global rights to cevidoplenib, an oral SYK inhibitor, from Oscotec for immune thrombocytopenia and other indications.
• Together, these updates reshape Agios’s mix of commercial products and pipeline assets, trading one unpromising program for an expanded marketed franchise and a new late-stage hematology candidate.
• Next, we’ll examine how licensing cevidoplenib and expanding PYRUKYND’s reach may influence Agios’s rare-disease investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.

Agios Pharmaceuticals Investment Narrative Recap

To own Agios today, you need to be comfortable backing a rare‑disease specialist built around mitapivat, while accepting ongoing losses and concentrated product risk. The key near term catalyst remains US regulatory progress and launch execution for PYRUKYND / AQVESME in thalassemia and potentially sickle cell disease. Recent news around tebapivat’s LR‑MDS setback and the cevidoplenib deal does not change that core focus, but it does add moving parts to an already complex story.

The most directly relevant update is the European Commission approval of PYRUKYND for thalassemia, which turns a major pipeline driver into a commercial asset across all EU member states. This matters because Agios generated only US$66,048,000 of revenue in the last reported year, against a US$422,603,000 net loss, so incremental, label‑driven PYRUKYND growth is central to any path toward a more sustainable P&L.

Yet, alongside this progress, investors should also be aware that the same thalassemia labeling highlights hepatocellular injury risk and the possibility of stricter monitoring requirements that could...

Agios Pharmaceuticals’ narrative projects $436.9 million revenue and $83.2 million earnings by 2029.

Uncover how Agios Pharmaceuticals' forecasts yield a $40.88 fair value, a 42% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming revenue could reach about US$465,100,000 by 2028, but if hepatotoxicity worries curb PYRUKYND adoption, that very bullish view of rapid, clean market uptake may look quite different, underscoring how your own risk tolerance and expectations can differ sharply from even the highest published forecasts.

Explore 2 other fair value estimates on Agios Pharmaceuticals - why the stock might be a potential multi-bagger!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Agios Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Agios Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agios Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.